Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Featured trial
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Background: Chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) are tumors of abnormal B cells that often affect elderly patients. Studies have identified critical factors required for the growth of CLL cells. First, CLL cells survive because they receive signals through the B-cell receptor. Second, CLL cells benefit from …

monoclonal antibodies
night sweats
lymphadenopathy
anemia
lymphoma
  • 169 views
  • 15 Apr, 2019
  • 1 location
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

(SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive

chronic lymphocytic leukemia refractory
TP53
lymphadenopathy
17p deletion
lymphoma
  • 229 views
  • 04 Oct, 2022
  • 30 locations
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

the follow-ing risk factors: 17p-deletion, TP53-mutation or complex karyotype).

obinutuzumab
TP53
acalabrutinib
venetoclax
platelet count
  • 0 views
  • 27 May, 2022
  • 2 locations
MInimal Residual Disease Adapted Strategy (MIDAS)

responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del

anemia
neutrophil count
granulocyte colony stimulating factor
platelet count
hypercalcemia
  • 0 views
  • 26 Apr, 2022
  • 51 locations
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

This phase I trial studies the best dose and how well copanlisib when given together with nivolumab works in treating patients with Richter's transformation or transformed indolent non-Hodgkin lymphoma. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal …

nivolumab
lymphadenopathy
monoclonal antibody therapy
r-chop
neutrophil count
  • 17 views
  • 09 Apr, 2022
  • 2 locations
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving …

cell transplantation
myeloid leukemia
remission
platelet count
white blood cells
  • 0 views
  • 25 May, 2022
  • 1 location
Optimizing PTCy Dose and Timing

Background Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of PTCy …

cell transplantation
chronic myelomonocytic leukaemia
myeloid leukemia
remission
cyclophosphamide
  • 42 views
  • 04 Oct, 2022
  • 1 location